Payment overview · 2025
General Payments
$101.09
1 reported records · 1 companies
Healthcare provider profile · identity verified
Rafael Antonio Bloise Espinal, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hospice and Palliative Medicine · NORWOOD, MA · NPI 1689933392
Verified facts
What the public records show
CMS Open Payments records show Rafael Antonio Bloise Espinal, MD received $101.09 in general payments during 2025 across 1 reported records.
ACADIA Pharmaceuticals Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Nuplazid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $101.09 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $101.09 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $101.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 322 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 34 |
| Furosemide | Furosemide | 157 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 147 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 30 |
| Lisinopril | Lisinopril | 138 | 27 |
| Omeprazole | Omeprazole | 129 | 24 |
| Gabapentin | Gabapentin | 122 | 25 |
| Potassium Chloride | Potassium Chloride | 122 | 27 |
| Jardiance | Empagliflozin | 108 | suppressed |
| Losartan Potassium | Losartan Potassium | 105 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 95 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 93 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 15 |
| Trazodone Hcl | Trazodone Hcl | 82 | 16 |
| Warfarin Sodium | Warfarin Sodium | 82 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 78 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | 11 |
| Famotidine | Famotidine | 64 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 60 | suppressed |
| Myrbetriq | Mirabegron | 57 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 57 | 12 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Lorazepam | Lorazepam | 52 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 48 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Carvedilol | Carvedilol | 42 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Prednisone | Prednisone | 38 | 16 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | suppressed |
| Latanoprost | Latanoprost | 33 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 32 | 15 |
| Montelukast Sodium | Montelukast Sodium | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 20 |
| Glipizide | Glipizide | 29 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Simvastatin | Simvastatin | 26 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 12 |
| Budesonide | Budesonide | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 22 | suppressed |
| Verapamil Sr | Verapamil Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 21 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Dalfampridine Er | Dalfampridine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Methadone Hcl | Methadone Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $101.09 · 1 records | ACADIA Pharmaceuticals Inc | NUPLAZID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error